Valeant Pharmaceuticals Intl Inc (VRX) Receives “Sector Perform” Rating from Royal Bank of Canada

Royal Bank of Canada restated their sector perform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) in a research report sent to investors on Monday morning, StockTargetPrices.com reports. They currently have a C$24.00 price target on the specialty pharmaceutical company’s stock.

Several other research firms also recently commented on VRX. Scotiabank restated a sector perform rating and issued a C$17.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, January 11th. TD Securities restated a hold rating and issued a C$18.50 price target on shares of Valeant Pharmaceuticals Intl in a research note on Friday, February 17th. Finally, Morgan Stanley downgraded shares of Valeant Pharmaceuticals Intl from an overweight rating to an equal weight rating in a research note on Thursday, December 15th.

Valeant Pharmaceuticals Intl (TSE:VRX) opened at 14.49 on Monday. The firm has a 50 day moving average of $17.83 and a 200-day moving average of $23.24. The company’s market capitalization is $5.04 billion. Valeant Pharmaceuticals Intl has a 52 week low of $13.82 and a 52 week high of $50.18.

ILLEGAL ACTIVITY WARNING: This news story was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/2450057/valeant-pharmaceuticals-intl-inc-vrx-receives-sector-perform-rating-from-royal-bank-of-canada-2.html.

In other news, Director Schutter Richard Urbain De acquired 10,000 shares of Valeant Pharmaceuticals Intl stock in a transaction on Wednesday, March 15th. The shares were purchased at an average cost of C$10.80 per share, for a total transaction of C$108,000.00.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Stock Target Prices

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Blackberry Returns as Stock Surges Following WannaCry
Blackberry Returns as Stock Surges Following WannaCry
Flight Attendants Accuse Frontier Airlines of Not Allowing Breast Feeding
Flight Attendants Accuse Frontier Airlines of Not Allowing Breast Feeding
General Motors’ Maven Launches in New York City
General Motors’ Maven Launches in New York City
Hyundai and Kia Recall Ordered by South Korea Officials
Hyundai and Kia Recall Ordered by South Korea Officials


© 2006-2017 Ticker Report. Google+.